LTRN
NASDAQLantern Pharma Inc.
News · 26 weeks42-73%
2025-12-142026-06-07
Mix3090d
- Other11(37%)
- SEC Filings11(37%)
- Earnings3(10%)
- Offering3(10%)
- Insider2(7%)
Latest news
25 items- PRLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung CancerExon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile. PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300. Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate. Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with amivantamab plus
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form D filed by Lantern Pharma Inc.D - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLCThe FDA raised no objections to Lantern's key proposed protocol amendments to the HARMONIC™ clinical trial. Amendments include: (1) enriching enrollment for patients with EGFR exon 21 L858R mutations; (2) extending LP-300 dosing to a maximum of eight cycles; and (3) transitioning to a single-arm study design — changes that align with emerging data and support a clearer regulatory and partnering path. EGFR exon 21 L858R mutations account for approximately 40% of all EGFR-mutant NSCLC globally and up to 50% in Asian populations — a molecularly defined subset that consistently experiences inferior outcomes when treated with current EGFR-targeted therapies relative to patients with exon
- SECLantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form 10-Q filed by Lantern Pharma Inc.10-Q - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business UpdatesDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple precision oncology programs Commercial introduction of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development Successful outcome from Type C meeting request with the FDA focused on the LP-300 HARMONIC™ Clinical Trial Pediatric brain cancer IND cleared by FDA for enrollment for Lantern Pharma subsidiary, Starlight Therape
- SECLantern Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- INSIDERDirector Keyser D Jeffrey bought $100,001 worth of shares (48,544 units at $2.06), increasing direct ownership by 106% to 94,303 units (SEC Form 4)4 - Lantern Pharma Inc. (0001763950) (Issuer)
- INSIDERDirector Schalop Lee Troy bought $100,001 worth of shares (48,544 units at $2.06) (SEC Form 4)4 - Lantern Pharma Inc. (0001763950) (Issuer)
- PRLantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering priced at the closing price with unregistered warrants exercisable at a 10% premium to the close and non-exercisable for the first six months Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced the closing of its previously announced registered direct offering of 2,135,923 shares of its common stock (or pre
- SECSEC Form 424B5 filed by Lantern Pharma Inc.424B5 - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering priced at the closing price with unregistered warrants exercisable at a 10% premium to the close and non-exercisable for the first six months Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,135,923 shares of i
- PRLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced that it will report its first quarter 2026 operating and financial results via press release to be issued on Friday, May 15. The press release will discuss financial results for the first quarter ended March 31, 2026 and provide operational updates on clinical trials and the development of the Company's AI platforms. About Lantern Pharma Lantern Pharma (NASDAQ:LTRN) is a clinical-stage AI-driven precision oncology company trans
- PRLantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™Planned additions are designed to expand and enhance withZeta.ai's capabilities, including: real-time, multi-omic computational analyses; simultaneous, highly parallel multi-agentic reasoning, and enterprise-grade institutional deployment. withZeta.ai is now commercially available with a fully enabled subscription payment model serving the full spectrum of the biomedical research and drug development community — and representing a new, non-dilutive revenue stream for Lantern Pharma shareholders in a market for AI-focused drug development and discovery tools and services valued at nearly $15 billion USD. Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage AI-driven precision oncology
- SECAmendment: SEC Form 10-K/A filed by Lantern Pharma Inc.10-K/A - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally360-Degree Small-Molecule Developability Profiling from a Single SMILES String in Seconds by characterizing and calculating 99 critical molecular features Capabilities are Fully Integrated into withZeta.ai® for Rare Cancer Drug Development Seeking Early Collaborations with Pharma Partners to Integrate Molecular Intelligence into Discovery Workflows Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR® AI platform, today announced the expansion of predictBBB.ai into a Large Quantitative Model (LQM) — a real-time quantitative intelligence engine now accessible to any researcher or drug development team, a
- PRLantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific DebutCEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 — Open to Investors, Researchers, and the Global Biomedical Community Registration Link & Details Can be Accessed Below Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic AI co-scientist platform, to be held on Thursday, April 30, 2026. The event follows the platform's scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks th
- PREmerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityLantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300's Novel Mechanism of Action and the Rapidly Evolving Post-TKI Standard of Care Among L858R patients in HARMONIC™, those who completed 6 doses or cycles of LP-300 demonstrated a higher median PFS than the overall L858R cohort and those patients that had only 4 doses or cycles of LP-300 Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing P
- PRLantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22Platform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City — April 16, 2026, 12:00–2:00 PM Eastern Public Demonstrations at AACR 2026, San Diego — Booth 5054, April 17–22 Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form SCHEDULE 13G filed by Lantern Pharma Inc.SCHEDULE 13G - Lantern Pharma Inc. (0001763950) (Subject)
- PRLantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform's capabilities and
- SECSEC Form 424B5 filed by Lantern Pharma Inc.424B5 - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form 10-K filed by Lantern Pharma Inc.10-K - Lantern Pharma Inc. (0001763950) (Filer)
LTRN FAQ
7 questionsWhat does Lantern Pharma Inc. do?
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain...Where does LTRN stock trade?
Lantern Pharma Inc. (LTRN) is listed on NASDAQ.What sector and industry is LTRN in?
Lantern Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lantern Pharma Inc. go public?
Lantern Pharma Inc. (LTRN) completed its IPO in 2020.What are analysts saying about LTRN?
Lantern Pharma Inc. has had 3 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $3600.00 price target on 2022-03-11. Recent price targets range from $3200.00 to $3600.00.What companies are similar to LTRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LTRN side-by-side with any of them on Quantisnow.How can I track LTRN on Quantisnow?
Quantisnow aggregates Lantern Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LTRN to receive live email and push alerts on every new disclosure.